AHA comments to HHS on 340B drug rebate models

The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B Program is a vital lifeline for hospitals, particularly those serving rural and low-income communities,” AHA said. “If HHS authorizes these proposed ‘rebate models,’ it would come at the expense of America’s most vulnerable patients and communities.” HHS recently announced that it will be “in a position to provide guidance” about the drug industry’s proposed use of “rebate models” by the end of May.
Related News Articles
Headline
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater…
Chairperson's File
Advocacy is such an important part of what we do as hospitals and health systems — and what the AHA does on behalf of our field — to help ensure that we get…
Headline
The AHA June 4 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law…
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…